SIGN UP
LOG IN
MARKET
DRUG
DRUG
Bright Minds Biosciences Inc
NASDAQ
1.150
-0.030
-2.54%
Opening 09:52 04/19 EDT
OPEN
1.140
PREV CLOSE
1.180
HIGH
1.160
LOW
1.140
VOLUME
1.23K
TURNOVER
0
52 WEEK HIGH
6.44
52 WEEK LOW
1.090
MARKET CAP
5.13M
P/E (TTM)
-0.8600
1D
5D
1M
3M
1Y
5Y
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 2d ago
Weekly Report: what happened at DRUG last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at DRUG last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at DRUG last week (0325-0329)?
Weekly Report · 04/01 09:38
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Bright Minds Biosciences’ Successful AGM & Stock Options Grant
TipRanks · 03/27 21:07
Weekly Report: what happened at DRUG last week (0318-0322)?
Weekly Report · 03/25 09:39
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.
Webull offers Bright Minds Biosciences Inc stock information, including NASDAQ: DRUG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRUG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading DRUG stock methods without spending real money on the virtual paper trading platform.